Cyted Health secures £44 million Series B funding to advance oesophageal cancer diagnostics
Cambridge-based molecular diagnostics company Cyted Health has completed a $44 million Series B financing round to accelerate commercial expansion of its minimally invasive oesophageal cancer detection platform across the United States, following successful deployment of over 35,000 tests within the NHS.
Cyted Health has secured substantial Series B financing to expand its pioneering gastrointestinal molecular diagnostics platform, with particular focus on early detection of oesophageal conditions through minimally invasive cellular collection techniques.
The $44 million funding round was led by EQT Life Sciences through its EQT Health Economics strategy, with co-leadership from Advent Life Sciences and British Business Bank. Existing investors Morningside and BGF provided continued support for the Cambridge-founded company.
Clinical validation drives commercial expansion
The financing will accelerate Cyted’s commercial expansion in the United States market whilst consolidating established success across the UK’s National Health Service. The company’s diagnostic platform centres on EndoSign®, an FDA 510(k)-cleared device that enables minimally invasive collection of oesophageal cells, coupled with advanced biomarker molecular testing. Cyted’s technology has demonstrated measurable clinical impact within the NHS, completing over 35,000 diagnostic tests and generating a robust portfolio of peer-reviewed publications documenting patient acceptability and real-world clinical outcomes. The clinical significance becomes apparent when considering that oesophageal cancer maintains a survival rate of merely 20%, positioning it among the most lethal malignancies globally.
Biomarker innovation addresses critical diagnostic gap
Founded by leading researchers at the University of Cambridge, Cyted specialises in minimally invasive cell collection combined with proprietary biomarker discovery to transform detection of pre-cancerous, cancerous, and inflammatory oesophageal conditions.
“This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting oesophageal diseases earlier,” said Marcel Gehrung, CEO and Co-founder of Cyted Health. “This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”
Strategic investment supports clinical validation studies
The financing coincides with Cyted’s ongoing DETECT-ME clinical validation study, which has been enrolling patients across multiple US sites since March 2025. This study aims to validate clinical performance of Cyted’s newest assays and molecular tests for oesophageal condition detection using the EndoSign platform.
Bruno Holthof, Partner at EQT Life Sciences, commented: “Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide. Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we’re delighted to add the company to our portfolio.”
The investment reflects growing recognition of molecular diagnostics’ role in early cancer detection, particularly for conditions with historically poor prognostic outcomes.
